@article{7b2f2409446b4e50bd021cf60d5c867c,
title = "Practical application of DaTQUANT with optimal threshold for diagnostic accuracy of dopamine transporter SPECT",
abstract = "Evaluation of Parkinsonian Syndromes (PS) with Ioflupane iodine-123 dopamine transporter single photon emission computed tomography (DaT-SPECT), in conjunction with history and clinical examination, aids in diagnosis. FDA-approved, semi-quantitative software, DaTQUANT{\texttrademark} (GE Healthcare, Chicago, IL, USA) is available to assist in interpretation. This study aims to evaluate the optimal variables and thresholds of DaTQUANT to yield the optimal diagnostic accuracy. It is a retrospective review with three different patient populations. DaT-SPECT images from all three study groups were evaluated using DaTQUANT{\texttrademark} software, and both single and multi-variable logistic regression were used to model PS status. The optimal models were chosen via accuracy, sensitivity, and specificity, then evaluated on the other study groups. Among single variable models, the posterior putamen yielded the highest accuracy (84% to 95%), while balancing sensitivity and specificity. Multi-variable models did not substantially improve the accuracy. When the optimal single variable models for each group were used to evaluate the remaining two groups, comparable results were achieved. In typical utilization of DaT-SPECT for differentiation between nigrostriatal degenerative disease (NSDD) and non-NSDD, the posterior putamen was the single variable that yielded the highest accuracy across three different patient populations. The posterior putamen{\textquoteright}s recommended thresholds for DaTQUANT are SBR ≤ 1.0, z-score of ≤−1.8 and percent deviation ≤ −0.34.",
keywords = "DaT-SPECT, DaTQUANT, FP-CiT, Ioflupane, Parkinson, Quantification",
author = "Matthew Neill and Fisher, {Julia M.} and Christine Brand and Hong Lei and Sherman, {Scott J.} and Chou, {Ying Hui} and Kuo, {Phillip H.}",
note = "Funding Information: This manuscript was supported by a grant from General Electric Healthcare, grant number 4252270. The authors would like to thank James Reynolds CNMT for his assistance with quantifying the scans. Data used in the preparation of this article were obtained from the Parkinson Progression Markers Initiative (PPMI) database: http://www.ppmi-info.org (accessed on 31 December 2013). For up-to-date information on the study, visit www.ppmi-info.org. PPMI—a public-private partnership—is funded by the Michael J. Fox Foundation for Parkinson{\textquoteright}s Research and funding partners, including Abbvie, Acurex Therapeutics, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson{\textquoteright}s, Avid Radiopharmaceuticals, Bial Biotech, Biogen, Biolegend, Bristol Myers Squibb, Calico, Celgene, Dacapo Brainscience, Jenali, 4D Pharma PLC, Edmond J. Safra Philanthropic Foundations, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lilly, Lundbeck, Merck, Meso Scale Discovery, Neurocrine, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, and Voyager Therapeutics. Funding Information: Acknowledgments: The authors would like to thank James Reynolds CNMT for his assistance with quantifying the scans. Data used in the preparation of this article were obtained from the Parkinson Progression Markers Initiative (PPMI) database: http://www.ppmi-info.org (accessed on 31 December 2013). For up-to-date information on the study, visit www.ppmi-info.org. PPMI—a public-private partnership—is funded by the Michael J. Fox Foundation for Parkinson{\textquoteright}s Research and funding partners, including Abbvie, Acurex Therapeutics, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson{\textquoteright}s, Avid Radiopharmaceuticals, Bial Biotech, Biogen, Biolegend, Bristol Myers Squibb, Calico, Celgene, Dacapo Brainscience, Jenali, 4D Pharma PLC, Edmond J. Safra Philanthropic Foundations, GE Healthcare, Genentech, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen Neuroscience, Lilly, Lundbeck, Merck, Meso Scale Discovery, Neurocrine, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, and Voyager Therapeutics. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
month = dec,
doi = "10.3390/tomography7040081",
language = "English (US)",
volume = "7",
pages = "980--989",
journal = "Tomography",
issn = "2379-1381",
publisher = "Grapho Publications LLC",
number = "4",
}